Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
Gynecol Obstet Invest. 2013;75(4):263-7. doi: 10.1159/000349892. Epub 2013 Apr 17.
The purpose of this study was to investigate the prognostic significance of serum sCD163 in patients with epithelial ovarian cancer.
Preoperative serum samples from 55 patients with epithelial ovarian cancers were analyzed for sCD163 using a commercially available enzyme-linked immunosorbent assay kit. A Cox proportional hazard model was used to calculate hazard ratio (HR) and 95% confidence interval (CI) for disease-free survival (DFS) and overall survival (OS).
Median serum sCD163 levels were higher in patients with a high-grade tumor. High serum sCD163 levels (3.43 mg/l) were associated with poor prognostic factors such as advanced stage (p = 0.024) and positive peritoneal cytology (p = 0.015). Univariate survival analysis showed that elevated sCD163 levels were associated with short DFS (8.0 vs. 32.4 months, p = 0.04) and OS (19.7 vs. 40.0 months, p = 0.027). Multivariate survival analysis revealed that high serum sCD163 levels were negatively associated with DFS (HR 3.1, 95% CI 1.2-8.1, p = 0.039).
Our study shows that elevated serum sCD163 levels were associated with poor prognosis in patients with ovarian cancer.
The prognostic significance of serum sCD163 in patients with epithelial ovarian cancer is described.
本研究旨在探讨血清 sCD163 在卵巢上皮癌患者中的预后意义。
采用商业酶联免疫吸附试验试剂盒检测 55 例上皮性卵巢癌患者术前血清 sCD163。采用 Cox 比例风险模型计算无病生存（DFS）和总生存（OS）的风险比（HR）和 95%置信区间（CI）。
高级别肿瘤患者的血清 sCD163 中位水平较高。高水平的血清 sCD163（3.43mg/L）与预后不良因素相关，如晚期（p=0.024）和阳性腹腔细胞学（p=0.015）。单因素生存分析显示，sCD163 升高与 DFS 短（8.0 与 32.4 个月，p=0.04）和 OS 短（19.7 与 40.0 个月，p=0.027）相关。多因素生存分析显示，高血清 sCD163 水平与 DFS 不良呈负相关（HR 3.1，95%CI 1.2-8.1，p=0.039）。
本研究表明，血清 sCD163 水平升高与卵巢癌患者预后不良相关。
描述了血清 sCD163 在卵巢上皮性癌患者中的预后意义。
